Phase 3 Clinical Trials With Primary Completion Dates in December 2017

This is a list of Phase 3 trials with primary completion dates in December 2017 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

Symbol Company Primary Completion Date Phase NCT ID Title
ACAD ACADIA Pharmaceuticals Inc. 2017-12-01 Phase 3 NCT00550238 A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis
ALKS Alkermes plc 2017-12-01 Phase 3 NCT02141399 A Long-Term Safety Study of ALKS 5461
AMRN Amarin Corporation plc 2017-12-01 Phase 3 NCT01492361 A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High Risk Patients With Hypertriglyceridemia and on Statin. The Primary Objective is to Evaluate the Effect of 4 g/Day AMR101 for Preventing the Occurrence of a First Major Cardiovascular Event.
AQXP Aquinox Pharmaceuticals, Inc. 2017-12-01 Phase 3 NCT02858453 Efficacy and Safety of 2 Doses of AQX-1125 in Subjects With Interstitial Cystitis / Bladder Pain Syndrome
ARGS Argos Therapeutics, Inc. 2017-12-01 Phase 3 NCT01582672 Phase 3 Trial of Autologous Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma
AXSM Axsome Therapeutics, Inc. 2017-12-01 Phase 3 NCT02504008 CREATE-1: A Study to Assess the Efficacy and Safety of AXS-02 in Patients With CRPS-1
CERS Cerus Corporation 2017-12-01 Phase 3 NCT01740531 Study to Evaluate Efficacy and Safety of S303 Treated Red Blood Cells (RBCs)in Subjects With Thalassemia Major Requiring Chronic RBC Transfusion
CTRV ContraVir Pharmaceuticals Inc 2017-12-01 Phase 3 NCT02412917 A Comparative Study of FV-100 vs. Valacyclovir for the Prevention of Post-Herpetic Neuralgia
CVM Cel-Sci Corporation 2017-12-01 Phase 3 NCT01265849 Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity
DEPO Depomed, Inc. 2017-12-01 Phase 3 NCT02081391 An Efficacy and Safety Study of Tapentadol in the Treatment of Post-operative Acute Pain Requiring Opioid Treatment in Pediatric Participants
EARS Auris Medical Holding AG 2017-12-01 Phase 3 NCT02040194 AM-101 in the Treatment of Acute Tinnitus 3
ENDP Endo International plc 2017-12-01 Phase 3 NCT01210352 Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Post Surgical Pediatric Subjects
EYEG Eyegate Pharmaceuticals, Inc. 2017-12-01 Phase 3 NCT02517619 Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Non-Infectious Anterior Uveitis
INSY Insys Therapeutics, Inc. 2017-12-01 Phase 3 NCT02318602 Cannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure Disorder
INSY Insys Therapeutics, Inc. 2017-12-01 Phase 3 NCT02138409 Fentanyl Sublingual Spray for the Treatment of Acute Procedure-related Pain in a Monitored Setting
KERX Keryx Biopharmaceuticals, Inc. 2017-12-01 Phase 3 NCT02492620 Ferric Citrate for the Transition From CKD Stage 4/5 to CKD Stage 5D
MD Mednax, Inc 2017-12-01 Phase 3 NCT02534077 Intravenous Fat Emulsion Comprised of Fish Oil in the Treatment of Parenteral Nutrition Induced Liver Injury in Infants
MESO Mesoblast Limited 2017-12-01 Phase 3 NCT02336230 A Prospective Study of Remestemcel-L, Ex-vivo Cultured Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD
MMSI Merit Medical Systems, Inc. 2017-12-01 Phase 3 NCT01387932 HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
NBRV Nabriva Therapeutics plc 2017-12-01 Phase 3 NCT02813694 Study to Compare Lefamulin to Moxifloxacin for the Treatment of Adults With Pneumonia
NKTR Nektar Therapeutics 2017-12-01 Phase 3 NCT02367820 Long-Term Safety and Tolerability Study of NKTR-181 in Subjects With Chronic Low Back Pain or Chronic Non-Cancer Pain
OHRP Ohr Pharmaceuticals, Inc. 2017-12-01 Phase 3 NCT02727881 Efficacy and Safety Study of Squalamine Ophthalmic Solution in Subjects With Neovascular AMD
ONTX Onconova Therapeutics, Inc. 2017-12-01 Phase 3 NCT01928537 Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine
PEN Penumbra, Inc. 2017-12-01 Phase 3 NCT01636453 The Penumbra Liberty Trial: Safety and Effectiveness in the Treatment of Wide-Neck Intracranial Aneurysms
PTCT PTC Therapeutics, Inc. 2017-12-01 Phase 3 NCT02090959 Phase 3 Extension Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy
PTCT PTC Therapeutics, Inc. 2017-12-01 Phase 3 NCT01557400 Study of Ataluren for Previously Treated Patients With nmDBMD in Europe, Israel, Australia, and Canada
RVNC Revance Therapeutics, Inc. 2017-12-01 Phase 3 NCT03014635 Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines
RVNC Revance Therapeutics, Inc. 2017-12-01 Phase 3 NCT03014622 Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines
SGEN Seattle Genetics, Inc. 2017-12-01 Phase 3 NCT01777152 ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas
SNGX Soligenix, Inc. 2017-12-01 Phase 3 NCT02448381 FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides)
SPPI Spectrum Pharmaceuticals, Inc. 2017-12-01 Phase 3 NCT02953340 Trial of SPI-2012 Versus Pegfilgrastim in the Management of Chemotherapy Induced Neutropenia in Early- Stage BReast Cancer Patients Receiving Docetaxel and Cyclophosphamide (RECOVER)
TTPH Tetraphase Pharmaceuticals, Inc. 2017-12-01 Phase 3 NCT02784704 Efficacy and Safety Study of Eravacycline Compared With Meropenem in Complicated Intra-abdominal Infections
VBLT Vascular Biogenics Ltd. 2017-12-01 Phase 3 NCT02511405 A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE)
VTL Vital Therapies, Inc. 2017-12-01 Phase 3 NCT02612428 Randomized, Open-Label, Multicenter, Controlled, Pivotal Study to Assess Safety and Efficacy of ELAD in Subjects w/ AILD